[Translation] A Phase I, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerability, and Pharmacokinetics of Troriluzole (BHV-4157) 280 mg Following Single and Multiple Dosing in Healthy Chinese Subjects Research
主要目的:评估在中国健康受试者中单次(280 mg)和多次(280 mg/日,连续5天)给药Troriluzole后的安全性和耐受性。
次要目的:评估在中国健康受试者中单次(280 mg)和多次(280 mg/日,连续5天) 给药Troriluzole后利鲁唑的药代动力学(PK)特征。
[Translation] Main objective: To evaluate the safety and tolerability of single (280 mg) and multiple (280 mg/day, 5 consecutive days) dosing of Troriluzole in healthy Chinese subjects.
Secondary objective: To evaluate the pharmacokinetic (PK) profile of riluzole following single (280 mg) and multiple (280 mg/day, 5 consecutive days) dosing of Troriluzole in healthy Chinese subjects.